

# Stuart McPherson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5094945/stuart-mcpherson-publications-by-year.pdf>  
**Version:** 2024-04-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85 papers	3,934 citations	25 h-index	62 g-index
113 ext. papers	5,136 ext. citations	6.1 avg, IF	5.62 L-index

#	Paper	IF	Citations
85	Viral hepatitis in 2021: The challenges remaining and how we should tackle them.. <i>World Journal of Gastroenterology</i> , <b>2022</b> , 28, 76-95	5.6	1
84	Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease. <i>American Journal of the Medical Sciences</i> , <b>2021</b> ,	2.2	
83	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. <i>Efficacy and Mechanism Evaluation</i> , <b>2021</b> , 8, 1-90	1.7	
82	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , <b>2021</b> , 6, 93	4.8	0
81	Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial. <i>BMJ Open</i> , <b>2021</b> , 11, e045922	3	78
80	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , <b>2021</b> , 6, 93	4.8	2
79	Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , <b>2021</b> , 8,	3.9	2
78	Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 168-176	3.4	1
77	Persistent Hepatitis E virus infection across England and Wales 2009-2017: Demography, virology and outcomes. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 420-430	3.4	4
76	Progress towards micro-elimination of hepatitis C in the custodial setting. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 300-301	3.4	2
75	Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease.. <i>Frontline Gastroenterology</i> , <b>2021</b> , 12, 578-585	2.6	2
74	The pathway to better primary care for chronic liver disease. <i>British Journal of General Practice</i> , <b>2021</b> , 71, 180-182	1.6	0
73	Embedding assessment of liver fibrosis into routine diabetic review in primary care. <i>JHEP Reports</i> , <b>2021</b> , 3, 100293	10.3	3
72	Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e20491	7.6	1
71	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , <b>2020</b> , 158, 1611-1625.e12	13.3	234
70	High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 449-452	3.4	11
69	Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00231	4.2	14

68	Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. <i>BMJ Open Gastroenterology</i> , <b>2020</b> , 7,	3.9	3
67	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. <i>Translational Behavioral Medicine</i> , <b>2020</b> , 10, 1016-1030	3.2	14
66	Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 3403	19.7	3
65	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , <b>2019</b> , 1, 188-198	10.3	46
64	Convalescent plasma therapy for persistent hepatitis E virus infection. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 434-438	13.4	14
63	The degree of hepatic steatosis associates with impaired cardiac and autonomic function. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1203-1213	13.4	26
62	Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≥ 3 in a Single-Arm, Open-Label, Multicenter Study. <i>Advances in Therapy</i> , <b>2019</b> , 36, 3458-3470	4.1	6
61	Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1364-1371.e3	6.9	19
60	Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England. <i>Journal of Public Health</i> , <b>2019</b> , 41, 700-706	3.5	5
59	Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 231-235	3.4	14
58	Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 101-108	3.4	35
57	Management of decompensated cirrhosis. <i>Clinical Medicine</i> , <b>2018</b> , 18, s60-s65	1.9	21
56	A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2018</b> , 8, 224-234	4.1	22
55	Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation. <i>Transplantation</i> , <b>2018</b> , 102, 15-20	1.8	41
54	Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. <i>Gut</i> , <b>2017</b> , 66, 1321-1328	19.2	128
53	Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1596-1603.e3	6.9	5
52	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. <i>Frontline Gastroenterology</i> , <b>2017</b> , 8, 252-259	2.6	15
51	Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1968-1971	6.9	17

50	Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 981-991	6.1	33
49	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S593	13.4	7
48	Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 96-102.e3	6.9	92
47	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 740-751	0.7	273
46	Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , <b>2017</b> , 16, 298-307	1	6
45	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175717	3.7	35
44	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 234-8	13.4	75
43	Improving testing for hepatitis B before treatment with rituximab. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 1172-8	2.2	11
42	Reply to "Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy". <i>Journal of Hepatology</i> , <b>2016</b> , 64, 753-4	13.4	3
41	Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 305-13	13.4	63
40	Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis-the first 24 h. <i>Frontline Gastroenterology</i> , <b>2016</b> , 7, 16-23	2.6	16
39	Decompensated alcohol related liver disease: acute management. <i>BMJ, The</i> , <b>2016</b> , 352, i124	5.9	25
38	Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?. <i>Journal of Public Health</i> , <b>2016</b> , 38, e554-e562	3.5	2
37	PTU-093a An Audit of Primary Prophylaxis Against Variceal Bleeding Amongst Patients with Cirrhosis. <i>Gut</i> , <b>2016</b> , 65, A100.3-A101	19.2	
36	PTH-107 Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance. <i>Gut</i> , <b>2016</b> , 65, A271.2-A272	19.2	
35	PTH-115 Increasing Access to Hepatitis C Treatment in The North East of England. <i>Gut</i> , <b>2016</b> , 65, A275-A276	19.2	
34	Implementation of a Rare bundle Improves the management of patients admitted to hospital with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 1030-1038	6.1	14
33	Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1148-55	13.4	626

32	PWE-120 High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (≥5 years) with naflD. <i>Gut</i> , <b>2015</b> , 64, A265.1-A265	19.2	
31	Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. <i>Postgraduate Medical Journal</i> , <b>2015</b> , 91, 92-101	2	14
30	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Postgraduate Medical Journal</i> , <b>2014</b> , 90, 254-66	2	7
29	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , <b>2014</b> , 5, 4309	17.4	362
28	PTH-090 Natural History Of NaflD: A Study Of 108 Patients With Paired Liver Biopsies. <i>Gut</i> , <b>2014</b> , 63, A249.2-A250	19.2	
27	Hepatitis B in pregnancy. <i>Frontline Gastroenterology</i> , <b>2014</b> , 5, 111-117	2.6	11
26	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. <i>Frontline Gastroenterology</i> , <b>2014</b> , 5, 211-218	2.6	168
25	Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. <i>Clinical Medicine</i> , <b>2014</b> , 14, 551-5	1.9	5
24	Non-alcoholic fatty liver disease: a practical approach to treatment. <i>Frontline Gastroenterology</i> , <b>2014</b> , 5, 277-286	2.6	75
23	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1055-62	13.4	57
22	Improving access to treatment for patients with chronic hepatitis C through outreach. <i>Frontline Gastroenterology</i> , <b>2013</b> , 4, 125-129	2.6	4
21	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 1033-45	3.9	54
20	Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 638-44	3.4	24
19	Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 652-8	2.2	57
18	Cholestasis secondary to anabolic steroid use in young men. <i>BMJ, The</i> , <b>2012</b> , 344, e468	5.9	22
17	PMO-171 A pilot of targeted case finding for hepatitis B virus (HBV) and hepatitis C (HCV) in the British South Asian community. <i>Gut</i> , <b>2012</b> , 61, A143.1-A143	19.2	1
16	P54 CHASE-B (Chinese Hepatitis Awareness, Surveillance and Education): a pilot of targeted case finding for hepatitis B virus (HBV) in the British-Chinese community. <i>Gut</i> , <b>2011</b> , 60, A25-A26	19.2	2
15	P81 Pre-transplant histological assessment in patients with alcoholic liver disease does not predict risk of recidivism post liver transplantation. <i>Gut</i> , <b>2011</b> , 60, A37-A38	19.2	

14	OP11 Are simple non-invasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. <i>Gut</i> , <b>2011</b> , 60, A54-A55	19.2	
13	Undiagnosed chronic hepatitis B is prevalent in the british-chinese community of the north east (NE) of england. <i>Gut</i> , <b>2011</b> , 60, A241-A241	19.2	2
12	No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 319-27	4	14
11	How big a problem is non-alcoholic fatty liver disease?. <i>BMJ, The</i> , <b>2011</b> , 343, d3897	5.9	129
10	Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. <i>Gut</i> , <b>2010</b> , 59, 1265-9	19.2	499
9	Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. <i>Transplantation Proceedings</i> , <b>2010</b> , 42, 4573-7	1.1	8
8	OC-017 A comparison of non-invasive fibrosis scoring systems in patients with non-alcoholic fatty liver disease. <i>Gut</i> , <b>2010</b> , 59, A7.2-A8	19.2	
7	Combined approach for non-invasive measurement of liver pathology by MR. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 1083-1084	13.4	1
6	Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 389-97	13.4	133
5	Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 1046-54	13.4	41
4	An alcoholic patient who continues to drink: case outcome. <i>BMJ, The</i> , <b>2006</b> , 332, 276	5.9	4
3	Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. <i>Diseases of the Colon and Rectum</i> , <b>2006</b> , 49, 640-5	3.1	157
2	Postoperative methicillin-resistant Staphylococcus aureus enteritis following hysterectomy: a case report and review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2005</b> , 17, 1225-7	2.2	5
1	Acute hepatitis C in a nursing home resident. <i>Age and Ageing</i> , <b>2005</b> , 34, 188-9	3	